Product Information


  • Individuals 18 year and older


  • 2* x 0.5 ml doses given IM (preferably deltoid)
    • The 2nd dose should be given between 4 and 12 weeks after the 1st.
      • As of Oct 22, 2021, NACI advises an interval of at least 8 weeks between the 1st and 2nd doses is optimal.
      • Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a 2nd dose for earlier protection should be considered when deciding the interval.
      • Individuals who completed their primary vaccine series using the manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

    • *Individuals who received two doses of Vaxzevria™ as a primary series are eligible to receive an mRNA vaccine (Pfizer-BioNTech Comirnaty™ or Moderna Spikevax™) booster dose 5 months or later after completion of their primary series. Vaxzevria™ (only available through Public Health) could be given to those for whom there is a contraindication to an mRNA vaccine.

    • *The Ministry of Health has authorized additional doses for individuals who are immunocompromised/clinically vulnerable and meet eligibility criteria; additional doses have also been authorized for travel purposes. See details of eligibility criteria/intervals of additional doses in Saskatchewan here.

  • If any interval is longer than recommended, there is no reason to restart the series. Provide the next dose as soon as possible.

Adverse Effects

  • Only short to medium term data are available at this time. Surveillance will continue for long-term adverse effects.
  • The most commonly reported adverse effects included:  
    • injection site tenderness
    • injection site pain
    • fatigue
    • headache
    • myalgia
    • malaise
    • pyrexia
    • chills
    • arthralgia
    • nausea
  • Rare adverse effects
    • VITT
      • The combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been reported post-market following vaccination with AstraZeneca Vaxzevria™. This adverse event is being referred to as Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT).
      • Health Canada has released a safety alert; the product monograph now includes this information in the Warnings and Precautions section.
      • Health Canada is soliciting further data from AstraZeneca, will continue to monitor and will take further action if necessary. 
    • Capillary leak syndrome
      • Very rare cases of capillary leak syndrome (CLS) have been reported following immunization with AstraZeneca Vaxzevria™ COVID-19 vaccine. Some affected patients had a previous diagnosis of CLS. CLS is a serious, potentially fatal condition characterized by acute episodes of limb edema, hypotension, hemoconcentration and hypoalbuminemia. Individuals with a history of CLS should not receive AstraZeneca Vaxzevria™.
    • Guillain-Barré Syndrome
      • Very rare events of demyelinating disorders, such as Guillain-Barré Syndrome (GBS), have been reported following vaccination with AstraZeneca Vaxzevria™ during post-authorization use.
    • Thrombocytopenia
      • Cases of thrombocytopenia, including immune thrombocytopenia, have been reported following receipt of AstraZeneca Vaxzevria™. This differs from VITT in that these cases were not associated with thrombosis.

Drug Interactions

  • There are no known drug interactions. 

09 Dec 2021

  • Age
    • AstraZeneca Vaxzevria™ COVID-19 Vaccine is approved for use in persons 18 years of age and older. 

  • Serious adverse or allergic reaction to previous dose of viral vector COVID-19 vaccine unless determined safe by an allergist or other healthcare provider
    • Individuals who experienced a severe immediate allergic reaction (e.g. anaphylaxis) after a dose of viral vector COVID-19 vaccine can be subsequently vaccinated with an mRNA COVID-19 vaccine in a controlled setting after consulting with an allergist or another appropriate physician if risk assessment deems benefits outweigh risks for the individual and informed consent is provided. Individuals should be observed for at least 30 minutes after vaccination.
  • Reported hypersensitivity to one of the ingredients. See product monographs for ingredients. 
    • In individuals with a confirmed severe immediate allergic reaction (e.g., anaphylaxis) to a component of this vaccine or its container, consultation with an allergist is recommended before receiving the vaccine.
    • Polysorbate 80 is a potentially allergenic ingredient.

  • Individuals with a history of the following conditions should not receive this vaccine:
    • heparin-induced thrombocytopenia (HIT)
    • thrombosis associated with lupus anticoagulant (thrombotic antiphospholipid syndrome)
    • major venous or arterial thrombosis with thrombocytopenia following viral vector COVID-19 vaccine
    • capillary leak syndrome

  • It is recommended individuals with a history of cerebral venous sinus thrombosis (CVST) with thrombocytopenia only receive this vaccine if benefit outweighs risk; mRNA COVID-19 vaccine is preferred.

  • For individuals with a history of immune thrombocytopenia, platelet monitoring may be recommended following vaccination with a viral vector vaccine.
  • Pregnancy
    • As of May 21, 2021, Vaxzevria™ is not to be routinely offered to pregnant individuals and instead these individuals should receive mRNA vaccines (i.e. Pfizer-BioNTech Comirnaty™, Moderna Spikevax™). 
      • Vaxzevria™ can be offered if:
        • allergy to any of the mRNA vaccine components, or
        • mRNA vaccine is not readily available
      • The reason for this recommendation is concerns about increased complexity in medical care if Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) were to occur following a viral vector vaccine.
    • Receipt of Vaxzevria™ during pregnancy is not a reason to terminate pregnancy.

  • Currently feeling unwell with symptoms that could be COVID-19.
    • to avoid confusion if symptoms arise/worsen as they could be adverse effects of the vaccine or because of the underlying infection
    • to prevent potential transmission to others who are at the vaccine clinic/site (clients should be following public health quarantine recommendations)

  • Breastfeeding/Immunocompromised/Autoimmune Conditions
    • These populations were excluded from the initial vaccine trials such that we had no data on safety and efficacy of the vaccines in these populations when vaccination started and decisions were based on risk-benefit assessments.
    • Based on real world data indicating COVID-19 vaccines are safe in these populations, NACI’s recommendations for COVID-19 vaccination in these populations are now the same as those for the general adult population, which is to receive a complete series of mRNA vaccine and to complete a series initiated with Vaxzevria™ with mRNA vaccine.  
      • Regarding special populations, most of the data have come from mRNA vaccines.
      • However, Vaxzevria™ should be used if there are any contraindications to mRNA vaccine or if mRNA vaccine is not accessible.
    • See information in similarly titled tabs for the Pfizer-BioNTech Comirnaty™ and Moderna Spikevax™ vaccines
  • NACI (available under the COVID-19 tab): Recommendations on the use of COVID-19 vaccines; 22 Oct 2021
  • eHealth COVID-19 Immunization Manual: COVID-19 Vaccine Contraindications & Precautions Background Document

30 Nov 2021

Current Infection
  • Clients with current infection should not present for vaccination to prevent transmission to others at the vaccination clinic/site and should follow public health quarantine recommendations.
Past Infection
  • If acute symptoms have resolved and all quarantine orders have been followed, the individual can be vaccinated.

26 Oct 2021

  • Previous direction had been to separate COVID-19 vaccine from all other vaccines based on limited safety, reactogenicity and immunogenicity evidence.
  • The Ministry of Health is authorizing COVID-19 vaccine to be administered concomitantly with other vaccines; no intervals are required before or after COVID-19 vaccine administration and another vaccine.
    • The Ministry of Health closely monitored simultaneous administration of COVID-19 and other vaccines as implemented in other jurisdictions over the past few months. No additional safety risks or adverse events following immunization have been identified by simultaneous administration of these vaccines.
    • This directive ensures that individuals have the opportunity to be immunized against COVID-19 when they are eligible to receive other vaccines such as influenza and school-aged vaccines.
  • NACI recommends that, in adolescents and adults, COVID-19 vaccines may be given at the same time as, or any time before or after, other vaccines, including live, non-live, adjuvanted or unadjuvanted vaccines.
  • Separate injection sites should be used when administering > 1 vaccine
    • Preferably use two different limbs but if need to inject >1 vaccine into the same limb, separate the two injection sites by at least 2.5 cm (1 inch).

 30 Nov 2021